157 related articles for article (PubMed ID: 33363254)
21. Discovery of potential small molecular SARS-CoV-2 entry blockers targeting the spike protein.
Wang L; Wu Y; Yao S; Ge H; Zhu Y; Chen K; Chen WZ; Zhang Y; Zhu W; Wang HY; Guo Y; Ma PX; Ren PX; Zhang XL; Li HQ; Ali MA; Xu WQ; Jiang HL; Zhang LK; Zhu LL; Ye Y; Shang WJ; Bai F
Acta Pharmacol Sin; 2022 Apr; 43(4):788-796. PubMed ID: 34349236
[TBL] [Abstract][Full Text] [Related]
22. Potential natural products that target the SARS-CoV-2 spike protein identified by structure-based virtual screening, isothermal titration calorimetry and lentivirus particles pseudotyped (Vpp) infection assay.
Chen GY; Pan YC; Wu TY; Yao TY; Wang WJ; Shen WJ; Ahmed A; Chan ST; Tang CH; Huang WC; Hung MC; Yang JC; Wu YC
J Tradit Complement Med; 2022 Jan; 12(1):73-89. PubMed ID: 34549024
[TBL] [Abstract][Full Text] [Related]
23. Macrolides May Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Entry into Cells: A Quantitative Structure Activity Relationship Study and Experimental Validation.
Galvez J; Zanni R; Galvez-Llompart M; Benlloch JM
J Chem Inf Model; 2021 Apr; 61(4):2016-2025. PubMed ID: 33734704
[TBL] [Abstract][Full Text] [Related]
24. Virtual screening and in vitro validation of natural compound inhibitors against SARS-CoV-2 spike protein.
Power H; Wu J; Turville S; Aggarwal A; Valtchev P; Schindeler A; Dehghani F
Bioorg Chem; 2022 Feb; 119():105574. PubMed ID: 34971947
[TBL] [Abstract][Full Text] [Related]
25. Identification of Potential SARS-CoV-2 Main Protease and Spike Protein Inhibitors from the Genus
Abouelela ME; Assaf HK; Abdelhamid RA; Elkhyat ES; Sayed AM; Oszako T; Belbahri L; El Zowalaty AE; Abdelkader MSA
Molecules; 2021 Mar; 26(6):. PubMed ID: 33801151
[TBL] [Abstract][Full Text] [Related]
26.
Teli DM; Shah MB; Chhabria MT
Front Mol Biosci; 2020; 7():599079. PubMed ID: 33542917
[TBL] [Abstract][Full Text] [Related]
27. In Silico Screening of Natural Products as Potential Inhibitors of SARS-CoV-2 Using Molecular Docking Simulation.
Hossain R; Sarkar C; Hassan SMH; Khan RA; Arman M; Ray P; Islam MT; Daştan SD; Sharifi-Rad J; Almarhoon ZM; Martorell M; Setzer WN; Calina D
Chin J Integr Med; 2022 Mar; 28(3):249-256. PubMed ID: 34913151
[TBL] [Abstract][Full Text] [Related]
28. In a search for potential drug candidates for combating COVID-19: computational study revealed salvianolic acid B as a potential therapeutic targeting 3CLpro and spike proteins.
Elmaaty AA; Darwish KM; Khattab M; Elhady SS; Salah M; Hamed MIA; Al-Karmalawy AA; Saleh MM
J Biomol Struct Dyn; 2022; 40(19):8866-8893. PubMed ID: 33928870
[TBL] [Abstract][Full Text] [Related]
29. Phytoconstituents from Moringa oleifera fruits target ACE2 and open spike glycoprotein to combat SARS-CoV-2: An integrative phytochemical and computational approach.
Siddiqui S; Ahmad R; Alaidarous M; Zia Q; Ahmad Mir S; Alshehri B; Srivastava A; Trivedi A
J Food Biochem; 2022 May; 46(5):e14062. PubMed ID: 35043973
[TBL] [Abstract][Full Text] [Related]
30. Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach.
Gupta Y; Kumar S; Zak SE; Jones KA; Upadhyay C; Sharma N; Azizi SA; Kathayat RS; Poonam ; Herbert AS; Durvasula R; Dickinson BC; Dye JM; Rathi B; Kempaiah P
Bioorg Med Chem; 2021 Oct; 47():116393. PubMed ID: 34509862
[TBL] [Abstract][Full Text] [Related]
31. Screening of inhibitors against SARS-CoV-2 spike protein and their capability to block the viral entry mechanism: A viroinformatics study.
Farouk AE; Baig MH; Khan MI; Park T; Alotaibi SS; Dong JJ
Saudi J Biol Sci; 2021 Jun; 28(6):3262-3269. PubMed ID: 33654454
[TBL] [Abstract][Full Text] [Related]
32. Development and Evaluation of Peptidomimetic Compounds against SARS-CoV-2 Spike Protein: An in silico and in vitro Study.
Zarei O; Kleine-Weber H; Hoffmann M; Hamzeh-Mivehroud M
Mol Inform; 2022 Jul; 41(7):e2100231. PubMed ID: 35068079
[TBL] [Abstract][Full Text] [Related]
33. Anthocyanin derivatives as potent inhibitors of SARS-CoV-2 main protease: An in-silico perspective of therapeutic targets against COVID-19 pandemic.
Fakhar Z; Faramarzi B; Pacifico S; Faramarzi S
J Biomol Struct Dyn; 2021 Oct; 39(16):6171-6183. PubMed ID: 32741312
[TBL] [Abstract][Full Text] [Related]
34. Molecular modeling study of natural products as potential bioactive compounds against SARS-CoV-2.
Ribeiro R; Botelho FD; Pinto AMV; La Torre AMA; Almeida JSFD; LaPlante SR; Franca TCC; Veiga-Junior VF; Dos Santos MC
J Mol Model; 2023 May; 29(6):183. PubMed ID: 37212923
[TBL] [Abstract][Full Text] [Related]
35. Plant-Derived Antiviral Compounds as Potential Entry Inhibitors against Spike Protein of SARS-CoV-2 Wild-Type and Delta Variant: An Integrative in SilicoApproach.
Ambrose JM; Kullappan M; Patil S; Alzahrani KJ; Banjer HJ; Qashqari FSI; Raj AT; Bhandi S; Veeraraghavan VP; Jayaraman S; Sekar D; Agarwal A; Swapnavahini K; Krishna Mohan S
Molecules; 2022 Mar; 27(6):. PubMed ID: 35335139
[TBL] [Abstract][Full Text] [Related]
36. A multiple-step
Zhai J; He X; Man VH; Sun Y; Ji B; Cai L; Wang J
Phys Chem Chem Phys; 2022 Feb; 24(7):4305-4316. PubMed ID: 35107459
[TBL] [Abstract][Full Text] [Related]
37. Computational profiling of natural compounds as promising inhibitors against the spike proteins of SARS-CoV-2 wild-type and the variants of concern, viral cell-entry process, and cytokine storm in COVID-19.
Kar P; Saleh-E-In MM; Jaishee N; Anandraj A; Kormuth E; Vellingiri B; Angione C; Rahman PKSM; Pillay S; Sen A; Naidoo D; Roy A; Choi YE
J Cell Biochem; 2022 May; 123(5):964-986. PubMed ID: 35342986
[TBL] [Abstract][Full Text] [Related]
38. Anti-COVID-19 drug candidates: A review on potential biological activities of natural products in the management of new coronavirus infection.
Prasansuklab A; Theerasri A; Rangsinth P; Sillapachaiyaporn C; Chuchawankul S; Tencomnao T
J Tradit Complement Med; 2021 Mar; 11(2):144-157. PubMed ID: 33520683
[TBL] [Abstract][Full Text] [Related]
39. Potential Coronaviral Inhibitors of the Nucleocapsid Protein Identified In Silico and In Vitro from a Large Natural Product Library.
Pohler A; Abdelfatah S; Riedl M; Meesters C; Hildebrandt A; Efferth T
Pharmaceuticals (Basel); 2022 Aug; 15(9):. PubMed ID: 36145267
[TBL] [Abstract][Full Text] [Related]
40. Identification of hACE2-interacting sites in SARS-CoV-2 spike receptor binding domain for antiviral drugs screening.
Hu X; Cui J; Chen J; Du S; Wang X; Zhang Y; Qian J; Chen H; Wei F; Cai Q; Jia J; Wu J
Virus Res; 2022 Nov; 321():198915. PubMed ID: 36084746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
